Sanofi-aventis Announces Settlement
of Eloxatin U.S. Patent litigation
Paris, France – April 1, 2010 - Sanofi-aventis (EURONEXT:SAN and NYSE: SNY) announced today that it has settled U.S.
patent infringement suits related to generic versions of Eloxatin (oxaliplatin) with certain defendants involved in the litigation.
Sanofi and Debiopharm, licensor of the involved patent rights, signed settlement agreements with Teva Pharmaceuticals USA,
Inc., Fresenius Kabi (formerly Dabur) and Sandoz (collectively, the “Generic Manufacturers”) - thus partially resolving the
litigation over certain formulations of Eloxatin (oxaliplatin) in the U.S. District Court for the District of New Jersey and the U.S.
District Court for the District of Columbia.
Under the terms of the proposed settlement, the Generic Manufacturers would cease selling their generic oxaliplatin products on
June 30, 2010, and would resume selling generic oxaliplatin products on August 9, 2012, under a license to re-enter the market.
The rest of the settlement provisions are confidential. Moreover, all of the settlement provisions, including the dates noted
above, are subject to contingencies which could enhance, diminish or eliminate the value of those settlements to the Group.
The lawsuits relate to the quality and formulation of oxaliplatin, available in the United States under the brand name Eloxatin .
The settlement agreements are subject to review by the Federal Trade Commission, the U.S. Department of Justice and the
Attorney General for the State of Michigan.
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to help
improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more
information, www.sanofi-aventis.us or www.sanofi-aventis.com
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 19